• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • Our Pillars
        • ARIKAYCE®
        • Brensocatib
        • TPIP
        • Early-Stage Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Feb 20, 2018
    Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent
  • Feb 15, 2018
    Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018
  • Feb 7, 2018
    Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference
  • Jan 26, 2018
    Insmed Announces Closing of Public Offering
  • Jan 24, 2018
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jan 23, 2018
    Insmed Announces Pricing of Public Offering of Convertible Senior Notes
  • Jan 22, 2018
    Insmed Announces Proposed Public Offering of Convertible Senior Notes
  • Jan 3, 2018
    Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations
    Interim results from INS-312 show that 28% of patients who previously received 6 months of guideline based therapy (GBT) alone achieved culture conversion following addition of ALIS to therapy, consistent with data from the INS-212 study
  • Nov 28, 2017
    Insmed to Present at the Nasdaq 37th Annual Investor Conference
  • Nov 22, 2017
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 8, 2017
    Insmed to Present at Two November Conferences
  • Nov 2, 2017
    Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update
    During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS (amikacin liposome inhalation suspension) in patients with NTM lung disease caused by MAC, a rare, progressive, destructive lung infection
  • Oct 25, 2017
    Insmed to Host Third Quarter 2017 Financial Results Conference Call on Thursday, November 2, 2017
  • Sep 19, 2017
    Insmed to Present at Two September Investor Conferences
  • Sep 11, 2017
    Insmed Announces Closing of Public Offering
  • Sep 6, 2017
    Insmed Announces Pricing of Public Offering of Common Stock
  • Sep 5, 2017
    Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)
    Study met primary endpoint of culture conversion (p < 0.0001)
  • Sep 5, 2017
    Insmed Announces Proposed Public Offering of Common Stock
  • Aug 3, 2017
    Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
    On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month
  • Jul 27, 2017
    Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
  • Jul 12, 2017
    Insmed to Host Analyst and Investor Day on July 19, 2017
  • Jun 13, 2017
    Insmed to Present at the JMP Securities Life Sciences Conference
  • Jun 8, 2017
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 15, 2017
    Insmed Announces Key Additions to its Executive Management Team
    Paolo Tombesi named as Chief Financial Officer
  • May 3, 2017
    Insmed Reports First Quarter 2017 Financial Results and Provides Business Update
    Advancing Toward Top-Line Results from CONVERT Study in 2H 2017
Show 5102550100 per page
  • «
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 27
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy